Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Timothy Affolter"'
Autor:
Timothy Affolter, Heather P Llewellyn, Derek W Bartlett, Qing Zong, Shuhua Xia, Vince Torti, Changhua Ji
Publikováno v:
PLoS ONE, Vol 14, Iss 5, p e0217276 (2019)
Cancer cells harness immune checkpoints such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase 1 (IDO1) to evade immune control. Checkpoint inhibitors have demonstrated dur
Externí odkaz:
https://doaj.org/article/e97358d427054704baa64ad8ebcb427c
Autor:
Catherine Lee, Ziyue Karen Jiang, Simon Planken, Lisa K. Manzuk, Roberto Ortiz, Michael Hall, Kavon Noorbehesht, Sripad Ram, Timothy Affolter, Gabriel E. Troche, Nathan T. Ihle, Theodore Johnson, Youngwook Ahn, Manfred Kraus, Anand Giddabasappa
Publikováno v:
Molecular Cancer Therapeutics.
KRAS is one of the most commonly mutated oncogenes in lung, colorectal, and pancreatic cancers. Recent clinical trials directly targeting KRAS G12C presented encouraging results for a large population of non-small cell lung cancer (NSCLC), but resist
Autor:
James G. Christensen, Anthony Wong, Dana Buckman, Peter O'Brien, Kenneth Zasadny, Mary Spilker, Carleen Cullinane, Neeta R. Fahey, Timothy Affolter, Maruja E. Lira, Tim Nichols, Patrick B. Lappin, Qin Zhang, Cory L. Painter, Kyle Kuszpit, Wenlin Li, Zhengming Yan, Cathy C. Zhang
CCR Translation for This Article from [18F]FLT–PET Imaging Does Not Always “Light Up” Proliferating Tumor Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96968392700e4f56dcc13cde90952e86
https://doi.org/10.1158/1078-0432.22444500
https://doi.org/10.1158/1078-0432.22444500
Autor:
James G. Christensen, Anthony Wong, Dana Buckman, Peter O'Brien, Kenneth Zasadny, Mary Spilker, Carleen Cullinane, Neeta R. Fahey, Timothy Affolter, Maruja E. Lira, Tim Nichols, Patrick B. Lappin, Qin Zhang, Cory L. Painter, Kyle Kuszpit, Wenlin Li, Zhengming Yan, Cathy C. Zhang
Purpose: [18F]FLT (3′-Fluoro-3′ deoxythymidine)–PET imaging was proposed as a tool for measuring in vivo tumor cell proliferation. The aim of this article was to validate the use of [18F]FLT–PET imaging for measuring xenograft proliferation a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f1e7e14da69a2c102f14c5e07ac9966
https://doi.org/10.1158/1078-0432.c.6520203.v1
https://doi.org/10.1158/1078-0432.c.6520203.v1
Autor:
James G. Christensen, Anthony Wong, Dana Buckman, Peter O'Brien, Kenneth Zasadny, Mary Spilker, Carleen Cullinane, Neeta R. Fahey, Timothy Affolter, Maruja E. Lira, Tim Nichols, Patrick B. Lappin, Qin Zhang, Cory L. Painter, Kyle Kuszpit, Wenlin Li, Zhengming Yan, Cathy C. Zhang
PDF file - 77K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bb4a2d7a0567a63c068a952cf3da7db
https://doi.org/10.1158/1078-0432.22444497
https://doi.org/10.1158/1078-0432.22444497
Autor:
Tristan Wirtz, Catherine Lee, Tao Xie, Lisa Manzuk, Manfred Kraus, Christopher Dillon, Timothy Affolter, Anand Giddabasappa
Publikováno v:
Cancer Immunology Research. 10:P065-P065
Radiotherapy (RT) has traditionally been seen as a means to induce targeted tumor cell death, and more than 50% of all cancer patients receive RT. RT is also known to induce immune cell activation, and the advent of immunotherapeutic treatments such
Autor:
Elizabeth A. McMillan, Koleen Eisele, Christina Adams, John Chionis, Timothy Affolter, Nichol Miller, Monica Ramstetter, Christopher P. Dillon, Jonathan Almaden, Lynn Wang, Tim S. Wang, Stephen Dann, Todd VanArsdale, Smitha Pillai
Publikováno v:
Cancer Research. 81:2960-2960
Overcoming checkpoints to cell cycle control is the basis for tumorigenesis and malignant growth. Therefore, models that recapitulate clinically relevant cell cycle deregulation enhance our understanding of defined tumors subsets. Specifically, pancr
Autor:
Derek W. Bartlett, Heather P. Llewellyn, Shuhua Xia, Timothy Affolter, Vince Torti, Qing Zong, Changhua Ji
Publikováno v:
PLoS ONE, Vol 14, Iss 5, p e0217276 (2019)
PLoS ONE
PLoS ONE
Cancer cells harness immune checkpoints such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase 1 (IDO1) to evade immune control. Checkpoint inhibitors have demonstrated dur
Autor:
Wenyue Hu, Rosa L. Frias, Hovhannes J. Gukasyan, Alice T. Shaw, Valeria Fantin, Ryohei Katayama, Nathan V. Lee, Ruth W. Tang, Timothy Affolter, Eugene Lifshits, Ted William Johnson, Divya Bezwada, David P. Kodack, Lars D. Engstrom, Hieu Lam, Sidra Mahmood, Tod Smeal, Luc Friboulet, Rakesh K. Jain, Hui Wang, Melissa West, Dac M. Dinh, Bhushankumar Patel, Qiuhua Li, Konstantinos Tsaparikos, Helen Y. Zou, Justine L. Lam, Sergei Timofeevski, Shinji Yamazaki, Patrick B. Lappin, Justin F. Gainor, Shibing Deng, Jinwei Wang
Publikováno v:
Cancer Cell. 28:70-81
SummaryWe report the preclinical evaluation of PF-06463922, a potent and brain-penetrant ALK/ROS1 inhibitor. Compared with other clinically available ALK inhibitors, PF-06463922 displayed superior potency against all known clinically acquired ALK mut
Autor:
Melissa West, Victoria A. Appleman, Valeria Fantin, Michele McTigue, Sergei Timofeevski, Matthew D. Falk, Alexei Brooun, Scott Rp McDonnell, Tod Smeal, Al Charest, Wenyue Hu, Wei Liu, Ya-Li Deng, Katy A. Wong, Timothy C. Nichols, Justine L. Lam, Ping Jiang, Helen Y. Zou, Qiuhua Li, Lars D. Engstrom, Timothy Affolter, Ted William Johnson, Patrick B. Lappin
Publikováno v:
Proceedings of the National Academy of Sciences. 112:3493-3498
Oncogenic c-ros oncogene1 (ROS1) fusion kinases have been identified in a variety of human cancers and are attractive targets for cancer therapy. The MET/ALK/ROS1 inhibitor crizotinib (Xalkori, PF-02341066) has demonstrated promising clinical activit